Clicky

Kinnate Biopharma Inc.(KNTE)

Description: Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors for treating genomically defined cancers. The company's lead product candidate is KIN002787, which is a rapidly accelerated fibrosarcoma inhibitor that is in preclinical stage for the treatment of patients with lung cancer, melanoma, and other solid tumors. Its other products in preclinical stage include KIN003, which are small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors (FGFR)2 and FGFR3 genes; and small molecule research programs, including a Cyclin-Dependent Kinase 12 inhibitor in its KIN004 program. Kinnate Biopharma Inc. was founded in 2018 and is headquartered in San Diego, California.


Keywords: Cancer Solid Tumors Lung Cancer Melanoma Sarcoma Fibroblast Growth Factor Fibroblast Growth Factor Receptor Fibrosarcoma

Home Page: www.kinnate.com

KNTE Technical Analysis

103 Montgomery Street
San Francisco, CA 94129
United States
Phone: 858 299 4699


Officers

Name Title
Mr. Nima Farzan M.B.A. Pres, CEO & Director
Ms. Neha Krishnamohan CFO, Principal Accounting Officer and Exec. VP of Corp. Devel.
Mr. Mark A. Meltz COO, Gen. Counsel, Treasurer & Sec.
Ms. Priyanka Shah VP of Investor Relations & Communications
Ms. Barbara Warren VP of People & Culture
Dr. Richard Thomas Williams MBBS, Ph.D. Chief Medical Officer
Dr. Robert Kania Ph.D. Sr. VP of Drug Discovery
Mr. Jason Hampson M.D. VP and Head of Regulatory Affairs & Quality

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.0635
Price-to-Sales TTM: 0
IPO Date: 2020-12-03
Fiscal Year End: December
Full Time Employees: 86
Back to stocks